Direct oral anticoagulants: Analysis of worldwide use and popularity using Google Trends

Annals of Translational Medicine

Volumn 5, Issue 16, 2017, Pages

  Lippi, Giuseppe ^a   Mattiuzzi, Camilla ^b   Cervellin, Gianfranco ^c   Favaloro, Emmanuel J ^d  

^a UNIVERSITY OF VERONA   (Italy)

^b Provincial Agency for Health Services   (Italy)

^c UNIVERSITY HOSPITAL OF PARMA   (Italy)

^d WESTMEAD HOSPITAL   (Australia)

Author keywords

Anticoagulants; Direct oral anticoagulants (DOACs); Google Trends; Laboratory

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; EDOXABAN; FONDAPARINUX; HEPARIN; PRESCRIPTION DRUG; RIVAROXABAN; WARFARIN;

ARTICLE; AUSTRALIA; CONTROLLED STUDY; DRUG USE; EASTERN EUROPE; HUMAN; NORTH AMERICA; SEARCH ENGINE; TREND STUDY;

EID: 85027096211     PISSN: 23055839     EISSN: 23055847     Source Type: Journal    
DOI: 10.21037/atm.2017.06.65     Document Type: Article

References (27)

1. Wadhera RK, Russell CE, Piazza G. Cardiology patient page. Warfarin versus novel oral anticoagulants: how to choose? Circulation 2014;130:e191-3.
2. Franchini M, Liumbruno GM, Bonfanti C, et al. The evolution of anticoagulant therapy. Blood Transfus 2016;14:175-84.
3. Favaloro EJ, Lippi G. The new oral anticoagulants and the future of haemostasis laboratory testing. Biochem Med (Zagreb) 2012;22:329-41.
4. Lippi G, Favaloro EJ. Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus? Clin Chem Lab Med 2015;53:185-97.
5. Favaloro EJ, Pasalic L, Curnow J, et al. Laboratory monitoring or measurement of direct oral anticoagulants (DOACs): Advantages, limitations and future challenges. Curr Drug Metab 2017. [Epub ahead of print].
6. Lippi G, Favaloro EJ. Laboratory monitoring of directoral anticoagulants (DOACs)-The perfect storm? Ann Transl Med 2017;5:6.
7. Cervellin G, Benatti M, Bonfanti L, et al. Quality and safety issues of direct oral anticoagulants in the emergency department. Semin Thromb Hemost 2015;41:348-54.
8. Barnes GD, Lucas E, Alexander GC, et al. National Trends in Ambulatory Oral Anticoagulant Use. Am J Med 2015;128:1300-5.
9. Loo SY, Dell'Aniello S, Huiart L, et al. Trends in the prescription of novel oral anticoagulants in UK primary care. Br J Clin Pharmacol 2017. [Epub ahead of print].
10. Elewa H, Alhaddad A, Al-Rawi S, et al. Trends in oral anticoagulant use in Qatar: a 5-year experience. J Thromb Thrombolysis 2017;43:411-6.
11. Gadsbøll K, Staerk L, Fosbøl EL, et al. Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark. Eur Heart J 2017;38:899-906.
12. Renda G, Patti G, Sangiuolo R, et al. Management of thromboembolic risk in patients with atrial fibrillation in Italy: follow-up data from the PREFER in AF European Registry. G Ital Cardiol (Rome) 2016;17:922-31.
13. Chang SS, Dong JZ, Ma CS, et al. Current Status and Time Trends of Oral Anticoagulation Use Among Chinese Patients With Nonvalvular Atrial Fibrillation: The Chinese Atrial Fibrillation Registry Study. Stroke 2016;47:1803-10.
14. Kristoufek L. Can Google Trends search queries contribute to risk diversification? Sci Rep. 2013;3:2713.
15. Nuti SV, Wayda B, Ranasinghe I, et al. The Use of Google Trends in Health Care Research: A Systematic Review. Plos One 2014;9:e109583.
16. Crowson MG, Schulz K, Tucci DL. National Utilization and Forecasting of Ototopical Antibiotics: Medicaid Data Versus "Dr. Google". Otol Neurotol 2016;37:1049-54.
17. Gahr M, Uzelac Z, Zeiss R, et al. Linking Annual Prescription Volume of Antidepressants to Corresponding Web Search Query Data: A Possible Proxy for Medical Prescription Behavior? J Clin Psychopharmacol 2015;35:681-5.
18. Cervellin G, Comelli I, Lippi G. Is Google Trends a reliable tool for digital epidemiology? Insights from different clinical settings. J Epidemiol Glob Health 2017;7:185-9.
19. Simmering JE, Polgreen LA, Polgreen PM. Web search query volume as a measure of pharmaceutical utilization and changes in prescribing patterns. Res Social Adm Pharm 2014;10:896-903.
20. Favaloro E, Pasalic L, Lippi G. Replacing warfarin therapy with the newer direct oral anticoagulants, or simply a growth in anticoagulation therapy? Implications for Pathology testing. Pathology 2017. [Epub ahead of print].
21. Facchinetti R, DeGuidi G, Pitoni F, et al. Rapid and well tolerated action of idarucizumab for antagonizing dabigatran in a patient needing urgent thrombolysis: a case report. Blood Coagul Fibrinolysis 2017. [Epub ahead of print].
22. Pharmacodia. Available online: http://en.pharmacodia.com. Last access: June 1, 2017.
23. Weitz JI, Semchuk W, Turpie AG, et al. Trends in Prescribing Oral Anticoagulants in Canada, 2008-2014. Clin Ther 2015;37:2506-14.
24. Olesen JB, Sørensen R, Hansen ML, et al. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013. Europace 2015;17:187-93.
25. Komen J, Forslund T, Hjemdahl P, et al. Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis. Br J Clin Pharmacol 2017;83:642-52.
26. Harrington AR, Armstrong EP, Nolan PE Jr, et al. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke. 2013;44:1676-81.
27. Liu H, Zhang Z, Linhardt RJ. Lessons learned from the contamination of heparin. Nat Prod Rep 2009;26:313-21.